NCT03220347View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas

PHASE1TerminatedINTERVENTIONAL
Enrollment

139

Participants

Timeline

Start Date

July 24, 2017

Primary Completion Date

September 6, 2024

Study Completion Date

September 6, 2024

Conditions
Lymphoma, Non-HodgkinNeoplasms
Interventions
DRUG

CC-90010

CC-90010 is an oral, potent and reversible inhibitor of the epigenetic target bromodomain and extra-terminal (BET) proteins.

Trial Locations (11)

20089

Local Institution - 302, Rozzano (MI)

28040

Local Institution - 201, Madrid

28041

Local Institution - 202, Madrid

33076

Local Institution - 102, Bordeaux

47014

Local Institution - 303, Meldola

80131

Local Institution - 301, Napoli, Campania

94805

Local Institution - 100, Villejuif

1358550

Local Institution - 402, Koto-ku

2778577

Local Institution - 400, Kashiwa-shi

464-8681

Local Institution - 401, Chikusa-ku

08035

Local Institution - 200, Barcelona

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY

NCT03220347 - A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas | Biotech Hunter | Biotech Hunter